Science AI Journal
Medicine · Research topic

Open research questions in Cardiomyopathy and Myosin Studies

540 gap statements mined from Cardiomyopathy and Myosin Studies papers in our 7.9M-paper local library, which holds 2,380 papers on the topic — drawn mostly from each paper's own stated research gap, future-work, challenge and limitation notes, and its abstract. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one.

Choosing where to publish on Cardiomyopathy and Myosin Studies? See the ranked Medicine journals.

What the literature leaves open

  • Future multicenter investigations incorporating quantitative LGE analysis are warranted to clarify whether the extent of myocardial scar offers additional risk stratification beyond LVEF and can guide patient selection for ICD therapy.

    Long-Term Outcomes in Patients with Dilated Left Ventricular Non-Compaction Versus Dilated Cardiomyopathy: A Propensity Score Matching Study · 2026 · DOI

  • As a risk factor, a history of alcohol consumption may potentially exacerbate the outflow tract pressure gradient through its vasodilatory effects, although the precise mechanisms remain to be elucidated.

    A Nomogram Integrating Inflammatory Biomarkers and Echocardiographic Parameters for Predicting Left Ventricular Outflow Tract Obstruction Risk in Hypertrophic Cardiomyopathy · 2026 · DOI

  • One of the key limitations is the small size of the groups according to their genotypes, especially the TTNtv/lof group (five patients in total and only four eligible for serum TTN analysis).

    Titin Serum Level Is Elevated in Patients with Myocarditis Depending on Their Genetic Background · 2026 · DOI

  • Family screening in this context may be reasonable, though its broader applicability remains uncertain. Repolarization anomalies suggestive of underlying cardiomyopathy are uncommon when screening adolescents, hence why caution is warranted in such cases.

    Family screening for genetic cardiomyopathies in ECG-positive phenotype-negative adolescents: a joint clinical and genetic approach · 2026 · DOI

  • Although there are several studies describing patient perspectives toward genetic therapies for arrhythmogenic right ventricular cardiomyopathy, aneuploidies, retinal conditions, phenylketonuria, sickle cell disease, hemophilia, and spinal muscular atrophy, there is limited literature specifically addressing patients with inherited HCM or DCM.

    Patient perspectives on gene therapies and gene editing for familial cardiomyopathies · 2026 · DOI

  • Our study aligns with the themes in prior studies in finding that clinical severity of the participant, potential impact on quality of life, and limited knowledge regarding the efficacy, safety, and mechanism of the procedure influenced the hypothetical decision-making process for genetic therapies.

    Patient perspectives on gene therapies and gene editing for familial cardiomyopathies · 2026 · DOI

  • BackgroundEchocardiographic indices of diastolic dysfunction are routinely obtained in hypertrophic cardiomyopathy (HCM), but their relationships with cardiorespiratory fitness and long-term clinical outcomes remain poorly defined.

    Diastolic Dysfunction Predicts Cardiorespiratory Fitness and Clinical Outcomes in Hypertrophic Cardiomyopathy · 2026 · DOI

  • They support the concept of disease-specific and context-dependent genetic risk profiles, reinforcing the need for personalized approaches to risk stratification and surveillance in children at risk of cardiomyopathy.

    Cardiac Hypertrophy: A Comprehensive Review from Prenatal Life to Young Adulthood · 2025 · DOI

  • Although the specific mechanism of SAM was not investigated in this study, it is presumed that the LVOTO alleviation was achieved based on the effect observed in HOCM humans treated with disopyramide.

    Disopyramide Therapy in Cats with Obstructive Hypertrophic Cardiomyopathy Non-Responsive to Carvedilol · 2025 · DOI

  • Anticoagulation follows standard indications for atrial fibrillation and for documented apical thrombus; catheter ablation can reduce recurrent ventricular tachycardia in selected cases; advanced therapies such as ventricular assist devices and transplantation remain options in end-stage disease, while surgical resection of non-compacted myocardium is exceptional and supported by limited evidence.

    Left Ventricular Non-Compaction Cardiomyopathy: A Review of the Pathophysiology, Epidemiology, Diagnosis, Genetics, and Clinical Management · 2025 · DOI

  • Though distinct from adult-onset disease, it remains understudied, with considerable variability in presentation that complicates clinical decision-making.

    Rethinking Childhood-Onset Hypertrophic Cardiomyopathy: A Review of Molecular Mechanisms and Unique Therapy Considerations · 2025 · DOI

  • While the absolute difference between NCCM and DCM is relatively modest, these findings may reflect differences in the underlying pathophysiological mechanisms, which can be used to generate hypotheses and warrant further investigation.

    Decreased Aortic Elasticity in Noncompaction Cardiomyopathy Compared to Dilated Cardiomyopathy · 2025 · DOI

  • One limitation in our study is that the experimental design did not permit assessment of whether morphological remodeling of the nuclei precedes the development of HCM; hence, it is unclear whether this observation represents a primary driver or secondary consequence of the Tnnc1-p.

    Cardiomyocyte Nuclear Pleomorphism in a Mouse Model of Inherited Hypertrophic Cardiomyopathy · 2025 · DOI

  • Left ventricular (LV) reverse myocardial remodeling occurs following septal myectomy in hypertrophic obstructive cardiomyopathy (HOCM), but it remains unclear whether diffuse fibrosis is reversible during this period.

    Left ventricle myocardial remodeling following septal myectomy in patients with hypertrophic obstructive cardiomyopathy · 2025 · DOI

  • Dilated cardiomyopathy (DCM) represents a major cause of heart failure (HF), but current HF prediction models lack validation in DCM cohorts.

    Time-dependent prognostic improvement by late gadolinium enhancement in dilated cardiomyopathy · 2025 · DOI

  • The prognostic value of left ventricular (LV) myocardial trabecular complexity on cardiovascular magnetic resonance (CMR) in dilated cardiomyopathy (DCM) remains unknown.

    Prognostic value of left ventricular trabeculae fractal analysis in patients with dilated cardiomyopathy · 2024 · DOI

  • Lastly, several limitations of the present study should be acknowledged. Moreover, long-term follow-up data are limited, and more cases with extended follow-up are needed function.

    Endocardial thickening in dilated cardiomyopathy associated with FHL2 variant: a case report · 2026 · DOI

  • Data for assessing the ability of ECG to screen HCM in apparently healthy cats is scarce.

    Accuracy of 6-lead electrocardiography in identifying subclinical hypertrophic cardiomyopathy in cats · 2026 · DOI

  • Consensus is lacking on which endocardial borders to include when measuring left ventricular wall thickness (LVWT) in cats.

    Influence of including or excluding endocardial borders on left ventricular wall thickness measurements in cats · 2026 · DOI

  • The effect of transapical beating-heart septal myectomy (TA-BSM) on the improvement of LA function and atrioventricular coupling remains uncertain.

    Impact of transapical beating-heart septal myectomy on left atrial remodeling and atrioventricular coupling in hypertrophic obstructive cardiomyopathy · 2025 · DOI

  • However, the clinical significance of age-specific longitudinal changes in LGE is not well characterized in HCM.

    Accelerated myocardial fibrosis in young to middle-aged patients with hypertrophic cardiomyopathy · 2024 · DOI

  • The evolving understanding of cardiomyopathy genetics is poised to transform clinical practice by integrating rare, intermediate-effect, and common genetic variants into personalized risk models. A major goal is the development of comprehensive risk calculators that combine rare pathogenic variants, moderate-risk variants, PRSs, and clinical data to provide individualized and precise risk assessments.

    From Rare Genetic Variants to Polygenic Risk: Understanding the Genetic Basis of Cardiomyopathies · 2025 · DOI

  • These findings identify KDM5A-dependent epigenetic dysregulation as a driver of HF and support further investigation of KDM5A inhibition as a potential therapeutic strategy for LMNA-CMP and possibly other forms of HF characterized by maladaptive epigenetic remodeling.

    Histone Demethylase KDM5A Is Activated and Pathogenic in a Mouse Model of LMNA-Cardiomyopathy · 2026 · DOI

  • Together findings point to a novel role for ANKB in the regulation of cardiomyocyte structural development and support additional investigation into a link between p.

    Ankyrin-B regulates cardiomyocyte sarcomere organization and its protein-protein interactions are significantly altered by p.S646F expression · 2026 · DOI

  • In MVP-ComVE, higher segmental ECV% was not limited to the inferolateral/inferior LV wall, but was also demonstrated in atypical segments including the anterior/anterolateral wall…

    Interstitial fibrosis and arrhythmic mitral valve prolapse: Unraveling sex-based differences · 2024 · DOI

Most-cited papers in Cardiomyopathy and Myosin Studies

Most recent work

Find a gap in your own Cardiomyopathy and Myosin Studies sub-topic

This page shows what the Cardiomyopathy and Myosin Studies literature already flags as unresolved. To narrow it to your specific question, search the Research Gap Finder: the search is free with a free account and lists the papers closest to your topic first. Unlocking that topic (50 credits, charged once) fills the comparison table from our 7.9M-paper local library and writes the gaps from its rows.

Open the Research Gap Finder →

Related topics in Medicine

Artificial Intelligence in Healthcare and Education
4,869 open questions
Dementia and Cognitive Impairment Research
3,297 open questions
Cancer Immunotherapy and Biomarkers
2,687 open questions
Liver Disease Diagnosis and Treatment
2,481 open questions
Substance Abuse Treatment and Outcomes
2,366 open questions
Sports Performance and Training
2,276 open questions
Mosquito-borne diseases and control
2,124 open questions
Parkinson's Disease Mechanisms and Treatments
2,117 open questions
Open questions raised by papers listed on this page include: (1) Future multicenter investigations incorporating quantitative LGE analysis are warranted to clarify whether the extent of myocardial scar offers additional risk stratification beyond LVEF and can guide patient selection for ICD therapy (“Long-Term Outcomes in Patients with Dilated Left Ventricular Non-Compaction…”, 2026); (2) As a risk factor, a history of alcohol consumption may potentially exacerbate the outflow tract pressure gradient through its vasodilatory effects, although the precise mechanisms remain to be elucidated (“A Nomogram Integrating Inflammatory Biomarkers and Echocardiographic Parameters…”, 2026); (3) Long-term follow-up data are limited, and more cases with extended follow-up are needed function (“Endocardial thickening in dilated cardiomyopathy associated with FHL2 variant:…”, 2026); (4) Data for assessing the ability of ECG to screen HCM in apparently healthy cats is scarce (“Accuracy of 6-lead electrocardiography in identifying subclinical hypertrophic…”, 2026); (5) Consensus is lacking on which endocardial borders to include when measuring left ventricular wall thickness (LVWT) in cats (“Influence of including or excluding endocardial borders on left ventricular…”, 2026). 540 gap statements have been mined from Cardiomyopathy and Myosin Studies papers in our 7.9M-paper local library, which holds 2,380 papers on the topic; the gaps come from whichever of those papers state one. They are mostly the research gaps the authors state and the papers' abstracts, plus future-work, limitations and challenges passages. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 1,100,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? Acceptance odds for top, mid and open/emerging journals, in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck for prior publication across 7 sources and our local library.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

How Pre-Check worksHow AI Review works

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.